We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
BioHarvest Sciences Inc. (BHST - Free Report) shares ended the last trading session 5.2% higher at $5.90. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.1% loss over the past four weeks.
The rise in share price is attributable to positive investor sentiment around the company’s proprietary technology platform to grow plant-based molecules, without the need to grow the underlying plant.
This company is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of +57.1%. Revenues are expected to be $7.75 million, up 45.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For BioHarvest Sciences Inc., the consensus EPS estimate for the quarter has been revised 66.7% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on BHST going forward to see if this recent jump can turn into more strength down the road.
BioHarvest Sciences Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Apellis Pharmaceuticals, Inc. (APLS - Free Report) , closed the last trading session 0.5% lower at $19.33. Over the past month, APLS has returned -21.3%.
For Apellis Pharmaceuticals, the consensus EPS estimate for the upcoming report has changed +0.6% over the past month to -$0.35. This represents a change of +35.2% from what the company reported a year ago. Apellis Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?
BioHarvest Sciences Inc. (BHST - Free Report) shares ended the last trading session 5.2% higher at $5.90. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.1% loss over the past four weeks.
The rise in share price is attributable to positive investor sentiment around the company’s proprietary technology platform to grow plant-based molecules, without the need to grow the underlying plant.
This company is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of +57.1%. Revenues are expected to be $7.75 million, up 45.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For BioHarvest Sciences Inc., the consensus EPS estimate for the quarter has been revised 66.7% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on BHST going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
BioHarvest Sciences Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Apellis Pharmaceuticals, Inc. (APLS - Free Report) , closed the last trading session 0.5% lower at $19.33. Over the past month, APLS has returned -21.3%.
For Apellis Pharmaceuticals, the consensus EPS estimate for the upcoming report has changed +0.6% over the past month to -$0.35. This represents a change of +35.2% from what the company reported a year ago. Apellis Pharmaceuticals currently has a Zacks Rank of #3 (Hold).